Topical gel for nosebleeds in hereditary hemorrhagic telangiectasia (HHT)
Part of Blood & lymphatic, Ear, nose & throat, Genetic & congenital, Heart & circulation, Lungs & breathing clinical trials.
This trial tests a new topical gel (TOR-582) applied inside the nose to reduce nosebleeds in people with HHT. It may help by targeting the abnormal blood vessels that cause frequent bleeding.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older with a confirmed HHT diagnosis.
- You should have moderate nosebleeds: at least 4 nosebleeds per week, with total bleeding time of at least 60 minutes weekly.
- Your nosebleed pattern and routine care must have been stable for at least 3 months before starting.
- No use of sirolimus or other mTOR inhibitors (like everolimus or temsirolimus) in the past 3 months.
- You cannot be taking any blood thinners (except low-dose aspirin up to 81 mg per day) or have certain blood-related conditions.
- No severe nasal crusting or a hole in your nasal septum, and no nasal surgeries (like cautery or embolization) in the past 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called ATV-1601 in people with HHT, a genetic condition that causes abnormal bleeding and blood vessel problems. The drug aims to reduce bleeding and anemia caused by HHT.
This trial tests whether a plant-based ointment (B-sitosterol) applied inside the nose works better than a standard petroleum jelly to reduce recurring nosebleeds. If you have frequent nosebleeds without an obvious cause, this treatment might help you.
This trial tests an investigational drug, TX002100, for people with hereditary hemorrhagic telangiectasia (HHT) who need regular intravenous iron infusions or blood transfusions to manage bleeding. The goal is to see if it reduces the need for these supportive treatments.
This study looks at different management strategies for severe nosebleeds when the initial packing method has not worked for over 48 hours. It also measures the cost/benefit of these approaches to help improve care.
This trial tests whether a gel called timolol helps scalp wounds heal better and look nicer after Mohs surgery. It may reduce scarring and improve healing.
This trial tests whether nintedanib can reduce how often and how severe nosebleeds are in adults with hereditary hemorrhagic telangiectasia (HHT). It may help by calming blood-vessel problems that cause bleeding.
Hear when a new Epistaxis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.